DoHAC may expand continuous glucose monitoring subsidies to T2D patients on the back of MSAC’s cost analysis, expected in 2025, even though it could cost over a billion dollars.
DoHAC may expand continuous glucose monitoring subsidies to T2D patients on the back of MSAC’s cost analysis, expected in 2025, even though it could cost over a billion dollars.